These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 20389023)

  • 1. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.
    Corti D; Suguitan AL; Pinna D; Silacci C; Fernandez-Rodriguez BM; Vanzetta F; Santos C; Luke CJ; Torres-Velez FJ; Temperton NJ; Weiss RA; Sallusto F; Subbarao K; Lanzavecchia A
    J Clin Invest; 2010 May; 120(5):1663-73. PubMed ID: 20389023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    Throsby M; van den Brink E; Jongeneelen M; Poon LL; Alard P; Cornelissen L; Bakker A; Cox F; van Deventer E; Guan Y; Cinatl J; ter Meulen J; Lasters I; Carsetti R; Peiris M; de Kruif J; Goudsmit J
    PLoS One; 2008; 3(12):e3942. PubMed ID: 19079604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice.
    Muramatsu M; Yoshida R; Miyamoto H; Tomabechi D; Kajihara M; Maruyama J; Kimura T; Manzoor R; Ito K; Takada A
    PLoS One; 2013; 8(8):e71534. PubMed ID: 23977065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.
    Clementi N; De Marco D; Mancini N; Solforosi L; Moreno GJ; Gubareva LV; Mishin V; Di Pietro A; Vicenzi E; Siccardi AG; Clementi M; Burioni R
    PLoS One; 2011; 6(12):e28001. PubMed ID: 22162996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.
    Yoshida R; Igarashi M; Ozaki H; Kishida N; Tomabechi D; Kida H; Ito K; Takada A
    PLoS Pathog; 2009 Mar; 5(3):e1000350. PubMed ID: 19300497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4.
    Schuele C; Schmeisser F; Orr M; Meseda CA; Vasudevan A; Wang W; Weiss CD; Woerner A; Atukorale VN; Pedro CL; Weir JP
    Influenza Other Respir Viruses; 2023 May; 17(5):e13152. PubMed ID: 37246149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody.
    Wyrzucki A; Dreyfus C; Kohler I; Steck M; Wilson IA; Hangartner L
    J Virol; 2014 Jun; 88(12):7083-92. PubMed ID: 24719426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
    Li GM; Chiu C; Wrammert J; McCausland M; Andrews SF; Zheng NY; Lee JH; Huang M; Qu X; Edupuganti S; Mulligan M; Das SR; Yewdell JW; Mehta AK; Wilson PC; Ahmed R
    Proc Natl Acad Sci U S A; 2012 Jun; 109(23):9047-52. PubMed ID: 22615367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza A viruses.
    Boonsathorn N; Panthong S; Koksunan S; Chittaganpitch M; Phuygun S; Waicharoen S; Prachasupap A; Sasaki T; Kubota-Koketsu R; Yasugi M; Ono K; Arai Y; Kurosu T; Sawanpanyalert P; Ikuta K; Watanabe Y
    Biochem Biophys Res Commun; 2014 Sep; 452(3):865-70. PubMed ID: 25204499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.
    Sautto GA; Kirchenbaum GA; Abreu RB; Ecker JW; Pierce SR; Kleanthous H; Ross TM
    J Immunol; 2020 Jan; 204(2):375-385. PubMed ID: 31811019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient.
    Hu W; Chen A; Miao Y; Xia S; Ling Z; Xu K; Wang T; Xu Y; Cui J; Wu H; Hu G; Tian L; Wang L; Shu Y; Ma X; Xu B; Zhang J; Lin X; Bian C; Sun B
    Virology; 2013 Jan; 435(2):320-8. PubMed ID: 23084424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus.
    Huang J; Huang N; Fan M; Zhao L; Luo Y; Ding P; Tian M; Liu Q; Guo Y; Zhao J; Zheng Y; Zhang H; Ping J
    Virol J; 2020 Dec; 17(1):191. PubMed ID: 33287849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018.
    Okuda M; Yamayoshi S; Uraki R; Ito M; Hamabata T; Kawaoka Y
    Viruses; 2019 Apr; 11(4):. PubMed ID: 30987023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.